Why Early QC Planning Matters in Cell and Gene Therapy
Late-stage CMC setbacks often begin with early QC decisions that shape cell and gene therapy timelines, costs, and regulatory outcomes
-
By
-
Laurent Claisse
-
June 30, 2026
-
Clinical Scorecard: Why Early QC Planning Matters in Cell and Gene Therapy
At a Glance
| Category | Detail |
|---|
| Condition | Cell and Gene Therapy |
| Key Mechanisms | Quality Control (QC) strategies and risk-based approaches in manufacturing. |
| Target Population | Patients requiring cell and gene therapies. |
| Care Setting | Biologics manufacturing and quality assurance. |
Key Highlights
- 74% of Complete Response Letters from the FDA are due to manufacturing or quality deficiencies.
- Early development decisions in gene therapy have significant downstream consequences.
- QC strategies must be consistent and connected throughout the manufacturing lifecycle.
- Geographical considerations are critical in the execution of quality strategies across regions.
- Regulatory frameworks emphasize the importance of early QC planning.
Guideline-Based Recommendations
Diagnosis
Management
- Implement a risk-based QC strategy from development through commercial phases.
Monitoring & Follow-up
- Ensure continuity in QC strategies across all stages of development.
Risks
- Failure to align QC plans with manufacturing needs can lead to delays and increased costs.
Patient & Prescribing Data
Individuals receiving cell and gene therapies.
Quality control measures must be integrated early to avoid downstream issues.
Clinical Best Practices
- Design QC strategies that consider the volume of material and specific manufacturing needs.
- Plan for geographical differences in regulatory expectations during strategy development.
- Utilize validated workflows that connect testing methods to release decisions.
Related Resources & Content
